303 related articles for article (PubMed ID: 36713468)
1. Toxicity of Chimeric Antigen Receptor T Cells and its Management.
Wudhikarn K; Soh SY; Huang H; Perales MA
Blood Cell Ther; 2021 Oct; 4(Spec Edition):S1-S7. PubMed ID: 36713468
[TBL] [Abstract][Full Text] [Related]
2. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
4. Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.
Yoo JW
Blood Res; 2023 Apr; 58(S1):S20-S28. PubMed ID: 36891576
[TBL] [Abstract][Full Text] [Related]
5. A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist.
Ong SY; Baird JH
J Intensive Care Med; 2023 Oct; ():8850666231205264. PubMed ID: 37899577
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
Gu T; Hu K; Si X; Hu Y; Huang H
WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
[TBL] [Abstract][Full Text] [Related]
7. CAR-T Cell Therapy: the Efficacy and Toxicity Balance.
Chohan KL; Siegler EL; Kenderian SS
Curr Hematol Malig Rep; 2023 Apr; 18(2):9-18. PubMed ID: 36763238
[TBL] [Abstract][Full Text] [Related]
8. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
9. Recapitulated Late-Onset Inflammatory Toxicities and Progressive Dysautonomia with Persistence of Central Memory CD4+ Chimeric Antigen Receptor T Cells in a Case of Transformed Follicular Lymphoma: Case Report.
Nishimoto M; Takakuwa T; Kuno M; Makuuchi Y; Okamura H; Nakashima Y; Koh H; Namba H; Itoh Y; Hino M; Nakamae H
Acta Haematol; 2023; 146(4):338-342. PubMed ID: 37088083
[TBL] [Abstract][Full Text] [Related]
10. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.
Yang C; Nguyen J; Yen Y
J Biomed Sci; 2023 Oct; 30(1):89. PubMed ID: 37864230
[TBL] [Abstract][Full Text] [Related]
11. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
Sterner RC; Sterner RM
Front Immunol; 2022; 13():879608. PubMed ID: 36081506
[TBL] [Abstract][Full Text] [Related]
12. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
[TBL] [Abstract][Full Text] [Related]
13. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms and management of CAR T toxicity.
Ferreri CJ; Bhutani M
Front Oncol; 2024; 14():1396490. PubMed ID: 38835382
[TBL] [Abstract][Full Text] [Related]
15. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
Schubert ML; Schmitt M; Wang L; Ramos CA; Jordan K; Müller-Tidow C; Dreger P
Ann Oncol; 2021 Jan; 32(1):34-48. PubMed ID: 33098993
[TBL] [Abstract][Full Text] [Related]
16. [Toxicity after chimeric antigen receptor T-cell therapy : Overview and management of early and late onset side effects].
Garcia Borrega J; Heindel K; Göreci Y; Warnke C; Onur OA; Kochanek M; Schub N; Ayuk F; Wichmann D; Böll B
Internist (Berl); 2021 Jun; 62(6):611-619. PubMed ID: 34032877
[TBL] [Abstract][Full Text] [Related]
17. Neurological adverse effects of chimeric antigen receptor T-cell therapy.
Saleki K; Mohamadi MH; Alijanizadeh P; Rezaei N
Expert Rev Clin Immunol; 2023; 19(11):1361-1383. PubMed ID: 37578341
[TBL] [Abstract][Full Text] [Related]
18. Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy.
Zhao Y; Zhang X; Zhang M; Guo R; Zhang Y; Pu Y; Zhu H; Liu P; Zhang Y; He X; Lyu C; Lyu H; Xiao X; Zhao M
Ann Hematol; 2024 Mar; 103(3):969-980. PubMed ID: 38214708
[TBL] [Abstract][Full Text] [Related]
19. Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications.
Mucha SR; Rajendram P
Curr Oncol; 2023 May; 30(5):5003-5023. PubMed ID: 37232836
[TBL] [Abstract][Full Text] [Related]
20. In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy.
Garcia Borrega J; Gödel P; Rüger MA; Onur ÖA; Shimabukuro-Vornhagen A; Kochanek M; Böll B
Hemasphere; 2019 Apr; 3(2):e191. PubMed ID: 31723828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]